Primary sclerosing cholangitis (PSC) is a rare cholestatic liver disease characterized by chronic inflammation and progressive fibrosis of the biliary tree, leading to significant liver function impairment over time. There is a strong association with inflammatory bowel diseases (IBD), together representing a distinct and complex medical condition. Patients with PSC-IBD face a heightened risk of various cancers, particularly colorectal carcinoma (CRC) and cholangiocarcinoma (CCA) as the most common types. In this review, we aim to characterize the distinctive features of PSC-IBD-associated carcinomas. Cancer pathogenesis in PSC-IBD is shaped by various factors including dysregulated bile acid metabolism, gut dysbiosis, and unique immune responses. PSC-IBD-associated CRC is often right-sided and warrants vigilant monitoring due to its higher incidence and unique morphological features compared to CRC arising in the terrain of IBD alone. CCA shares substantial genetic similarities with extrahepatic CCA and poses diagnostic challenges since it is frequently detected at advanced stages due to symptom overlap with PSC. Besides, reliable predictive biomarkers for targeted therapy remain largely unexplored. The distinct molecular, genetic, and histopathological profiles of CRC and CCA in PSC-IBD underscore the complexity of these malignancies and highlight the need for continued research to develop precise therapeutic strategies.

Clinical and Transplant Pathology Centre Institute for Clinical and Experimental Medicine Prague 14021 Czech Republic

Department of Gastroenterology and Hepatology Institute for Clinical and Experimental Medicine Prague 14021 Czech Republic

Department of Internal Medicine 2nd Faculty of Medicine Charles University Prague 15000 Czech Republic

Department of Pathology and Molecular Medicine 3rd Faculty of Medicine Charles University and Thomayer Hospital Prague 14059 Czech Republic

Department of Pathology Royal Vinohrady Teaching Hospital Srobarova 1150 50 Prague 10000 Czech Republic

Experimental Medicine Centre Institute for Clinical and Experimental Medicine Prague 14021 Czech Republic

Institute of Pathology of the 1st Faculty of Medicine and General Teaching Hospital Prague 12800 Czech Republic

Zobrazit více v PubMed

Karlsen TH, Folseraas T, Thorburn D, Vesterhus M (2017) Primary sclerosing cholangitis - a comprehensive review. J Hepatol 67:1298–1323 PubMed DOI

Chapman R, Fevery J, Kalloo A, Nagorney DM, Boberg KM, Shneider B, Gores GJ (2010) Diagnosis and management of primary sclerosing cholangitis. Hepatology 51:660–678 PubMed DOI

Sano H, Nakazawa T, Ando T et al (2011) Clinical characteristics of inflammatory bowel disease associated with primary sclerosing cholangitis. J Hepatobiliary Pancreat Sci 18:154–161 PubMed DOI

Björnsson E, Boberg KM, Cullen S, Fleming K, Clausen OP, Fausa O, Schrumpf E, Chapman RW (2002) Patients with small duct primary sclerosing cholangitis have a favourable long term prognosis. Gut 51:731 PubMed DOI PMC

Schaeffer DF, Win LL, Hafezi-Bakhtiari S, Cino M, Hirschfield GM, El-Zimaity H (2013) The phenotypic expression of inflammatory bowel disease in patients with primary sclerosing cholangitis differs in the distribution of colitis. Dig Dis Sci 58:2608–2614 PubMed DOI

Loftus EV, Harewood GC, Loftus CG, Tremaine WJ, Harmsen WS, Zinsmeister AR, Jewell DA, Sandborn WJ (2005) PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut 54:91–96 PubMed DOI PMC

Mertz A, Nguyen NA, Katsanos KH, Kwok RM (2019) Primary sclerosing cholangitis and inflammatory bowel disease comorbidity: an update of the evidence. Ann Gastroenterol 32:124 PubMed PMC

Lundberg Båve A, Bergquist A, Bottai M, Warnqvist A, von Seth E, Nordenvall C (2021) Increased risk of cancer in patients with primary sclerosing cholangitis. Hepatol Int 15:1174–1182 PubMed DOI PMC

Yashiro M (2014) Ulcerative colitis-associated colorectal cancer. World J Gastroenterol: WJG 20:16389 PubMed DOI PMC

Murthy SK, Feuerstein JD, Nguyen GC, Velayos FS (2021) AGA clinical practice update on endoscopic surveillance and management of colorectal dysplasia in inflammatory bowel diseases: expert review. Gastroenterology 161:1043–1051.e4 PubMed DOI

Catanzaro E, Gringeri E, Burra P, Gambato M, (2023) Primary sclerosing cholangitis-associated cholangiocarcinoma: from pathogenesis to diagnostic and surveillance strategies. Cancers 15:4947. 10.3390/cancers15204947 PubMed PMC

Zheng HH, Jiang XL (2016) Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease: a meta-analysis of 16 observational studies. Eur J Gastroenterol Hepatol 28:383–390 PubMed DOI

Zhang R, Lauwers GY, Choi WT (2022) Increased risk of non-conventional and invisible dysplasias in patients with primary sclerosing cholangitis and inflammatory bowel disease. J Crohns Colitis 16:1825–1834 PubMed DOI

Rutter M, Saunders B, Wilkinson K, Rumbles S, Schofield G, Kamm M, Williams C, Price A, Talbot I, Forbes A (2004) Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 126:451–459 PubMed DOI

Itzkowitz SH, Yio X (2004) Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation Am J Physiol Gastrointest Liver Physiol. 10.1152/AJPGI.00079.2004 PubMed DOI

Frick A, Khare V, Paul G, Lang M, Ferk F, Knasmüller S, Beer A, Oberhuber G, Gasche C (2018) Overt increase of oxidative stress and DNA damage in murine and human colitis and colitis-associated neoplasia. Mol Cancer Res 16:634–642 PubMed DOI

Schottelius AJ, Dinter H (2006) Cytokines, NF-kappaB, microenvironment, intestinal inflammation and cancer. Cancer Treat Res 130:67–87 PubMed DOI

Shaw DG, Aguirre-Gamboa R, Vieira MC, et al (2023) Antigen-driven colonic inflammation is associated with development of dysplasia in primary sclerosing cholangitis. Nat Med 29(6):1520–1529. 10.1038/s41591-023-02372-x PubMed PMC

Wittek A, Steglich B, Casar C et al (2024) A gradient of intestinal inflammation in primary sclerosing cholangitis. Inflamm Bowel Dis 30:900–910 PubMed DOI

Sears CL, Geis AL, Housseau F (2014) Bacteroides fragilis subverts mucosal biology: from symbiont to colon carcinogenesis. J Clin Invest 124:4166–4172 PubMed DOI PMC

Cougnoux A, Dalmasso G, Martinez R et al (2014) Bacterial genotoxin colibactin promotes colon tumour growth by inducing a senescence-associated secretory phenotype. Gut 63:1932–1942 PubMed DOI

Kummen M, Holm K, Anmarkrud JA et al (2017) The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls. Gut 66:611–619 PubMed DOI

Dohlman AB, Klug J, Mesko M, Gao IH, Lipkin SM, Shen X, Iliev ID (2022) A pan-cancer mycobiome analysis reveals fungal involvement in gastrointestinal and lung tumors. Cell 185:3807–3822.e12 PubMed DOI PMC

Nguyen TT, Ung TT, Kim NH, Do JY (2018) Role of bile acids in colon carcinogenesis. World J Clin Cases 6:577 PubMed DOI PMC

Claessen MMH, Lutgens MWMD, Van Buuren HR et al (2009) More right-sided IBD-associated colorectal cancer in patients with primary sclerosing cholangitis. Inflamm Bowel Dis 15:1331–1336 PubMed DOI

Krugliak Cleveland N, Rubin DT, Hart J et al (2018) Patients with ulcerative colitis and primary sclerosing cholangitis frequently have subclinical inflammation in the proximal colon. Clin Gastroenterol Hepatol 16:68 PubMed DOI PMC

Wang YN, Li J, Zheng WY et al (2017) Clinical characteristics of ulcerative colitis-related colorectal cancer in Chinese patients. J Dig Dis 18:684–690 PubMed DOI

Navaneethan U, Kochhar G, Venkatesh PGK, Bennett AE, Rizk M, Shen B, Kiran RP (2013) Random biopsies during surveillance colonoscopy increase dysplasia detection in patients with primary sclerosing cholangitis and ulcerative colitis. J Crohns Colitis 7:974–981 PubMed DOI

Grimsdottir S, Attauabi M, Kristine Dahl E, Burisch J, Seidelin JB (2023) Systematic review with meta-analysis: the impact of cancer treatments on the disease activity of inflammatory bowel diseases. J Crohns Colitis 17:1139–1153 PubMed DOI

Lu C, Schardey J, Zhang T, Crispin A, Wirth U, Karcz KW, Bazhin AV, Andrassy J, Werner J, Kühn F (2022) Survival outcomes and clinicopathological features in inflammatory bowel disease-associated colorectal cancer: a systematic review and meta-analysis. Ann Surg 276:E319–E330 PubMed DOI

Choi WT, Yozu M, Miller GC, Shih AR, Kumarasinghe P, Misdraji J, Harpaz N, Lauwers GY (2020) Nonconventional dysplasia in patients with inflammatory bowel disease and colorectal carcinoma: a multicenter clinicopathologic study. Mod Pathol 33:933–943 PubMed DOI

Kamarádová K, Vošmiková H, Rozkošová K, Ryška A, Tachecí I, Laco J (2019) Morphological, immunohistochemical and molecular features of inflammatory bowel disease associated colorectal carcinoma and associated mucosal lesions – single institution experience. Pathol Res Pract 215:730–737 PubMed DOI

Liu X, Goldblum JR, Zhao Z, Landau M, Heald B, Pai R, Lin J (2012) Distinct clinicohistologic features of inflammatory bowel disease-associated colorectal adenocarcinoma: in comparison with sporadic microsatellite-stable and Lynch syndrome-related colorectal adenocarcinoma. Am J Surg Pathol 36:1228–1233 PubMed DOI

Muzny DM, Bainbridge MN, Chang K et al (2012) Comprehensive molecular characterization of human colon and rectal cancer. Nature 487:330–337 PubMed DOI PMC

Zhang R, Rabinovitch PS, Mattis AN, Lauwers GY, Choi WT (2023) DNA content abnormality frequently develops in the right/proximal colon in patients with primary sclerosing cholangitis and inflammatory bowel disease and is highly predictive of subsequent detection of dysplasia. Histopathology 83:116–125 PubMed DOI

Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: a cancer-prone chronic inflammatory disease | Cancer Research | American Association for Cancer Research. https://aacrjournals.org/cancerres/article/60/13/3333/506396/Increased-p53-Mutation-Load-in-Noncancerous-Colon. Accessed 15 Sep 2024 PubMed

Brentnall TA, Crispin DA, Rabinovitch PS, Haggitt RC, Rubin CE, Stevens AC, Burmer GC (1994) Mutations in the p53 gene: an early marker of neoplastic progression in ulcerative colitis. Gastroenterology 107:369–378 PubMed DOI

Nagase H, Nakamura Y (1993) Mutations of the APC adenomatous polyposis coli) gene. Hum Mutat 2:425–434 PubMed DOI

Olafsson S, McIntyre RE, Coorens T et al (2020) Somatic evolution in non-neoplastic IBD-affected colon. Cell 182:672–684.e11 PubMed DOI PMC

Chatila WK, Walch H, Hechtman JF et al (2023) Integrated clinical and genomic analysis identifies driver events and molecular evolution of colitis-associated cancers. Nat Commun 14:110 PubMed DOI PMC

De Krijger M, Carvalho B, Rausch C et al (2022) genetic profiling of colorectal carcinomas of patients with primary sclerosing cholangitis and inflammatory bowel disease. Inflamm Bowel Dis 28:1309–1320 PubMed DOI PMC

Wohl P, Hucl T, Drastich P et al (2013) Epithelial markers of colorectal carcinogenesis in ulcerative colitis and primary sclerosing cholangitis. World J Gastroenterol 19:2234–2241 PubMed DOI PMC

Sepulveda AR, Hamilton SR, Allegra CJ, et al (2017) Molecular biomarkers for the evaluation of colorectal cancer: guideline summary from the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology. 101200/JOP2017022152 13:333–337 PubMed

Dubé PE, Yan F, Punit S, Girish N, McElroy SJ, Washington MK, Polk DB (2012) Epidermal growth factor receptor inhibits colitis-associated cancer in mice. J Clin Invest 122:2780 PubMed DOI PMC

Hsu HC, Thiam TK, Lu YJ et al (2016) Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients. Oncotarget 7:22257 PubMed DOI PMC

Le DT, Uram JN, Wang H et al (2015) PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372:2509–2520 PubMed DOI PMC

Idos GE, Kwok J, Bonthala N, Kysh L, Gruber SB, Qu C (2020) The prognostic implications of tumor infiltrating lymphocytes in colorectal cancer: a systematic review and meta-analysis. Sci Rep 10:3360 PubMed DOI PMC

Michael-Robinson JM, Pandeya N, Walsh MD, Biemer-Huttmann AE, Eri RD, Buttenshaw RL, Lincoln D, Clouston AD, Jaas JR, Radford-Smith GL (2006) Characterization of tumour-infiltrating lymphocytes and apoptosis in colitis-associated neoplasia: comparison with sporadic colorectal cancer. J Pathol 208:381–387 PubMed DOI

Lewis JT, Talwalkar JA, Rosen CB, Smyrk TC, Abraham SC (2010) Precancerous bile duct pathology in end-stage primary sclerosing cholangitis, with and without cholangiocarcinoma. Am J Surg Pathol 34:27–34 PubMed DOI

Chung BK, Karlsen TH, Folseraas T (2018) Cholangiocytes in the pathogenesis of primary sclerosing cholangitis and development of cholangiocarcinoma. Biochim Biophys Acta Mol Basis Dis 1864:1390–1400 PubMed DOI

Chazouilleres O, Beuers U, Bergquist A, Karlsen TH, Levy C, Samyn M, Schramm C, Trauner M (2022) EASL clinical practice guidelines on sclerosing cholangitis. J Hepatol 77:761–806 PubMed DOI

Ishii Y, Sasaki T, Serikawa M et al (2013) Elevated expression of cyclooxygenase-2 and microsomal prostaglandin E synthase-1 in primary sclerosing cholangitis: ιmplications for cholangiocarcinogenesis. Int J Oncol 43:1073–1079 PubMed DOI

Lieshout R, Kamp EJCA, Verstegen MMA et al (2023) Cholangiocarcinoma cell proliferation is enhanced in primary sclerosing cholangitis: a role for IL-17A. Int J Cancer 152:2607–2614 PubMed DOI

Grant AJ, Lalor PF, Salmi M, Jalkanen S, Adams DH (2002) Homing of mucosal lymphocytes to the liver in the pathogenesis of hepatic complications of inflammatory bowel disease. Lancet 359:150–157 PubMed DOI

de Krijger M, Visseren T, Wildenberg ME, Hooijer GKJ, Verstegen MMA, van der Laan LJW, de Jonge WJ, Verheij J, Ponsioen CY (2020) Characterization of gut-homing molecules in non-endstage livers of patients with primary sclerosing cholangitis and inflammatory bowel disease. J Transl Autoimmun. 10.1016/J.JTAUTO.2020.100054 PubMed DOI PMC

Graham JJ, Mukherjee S, Yuksel M et al (2021) Aberrant hepatic trafficking of gut-derived T cells is not specific to primary sclerosing cholangitis. Hepatology 75:518–530 PubMed DOI PMC

Kiziltas S (2016) Toll-like receptors in pathophysiology of liver diseases. World J Hepatol 8:1354 PubMed DOI PMC

Gulamhusein AF, Eaton JE, Tabibian JH, Atkinson EJ, Juran BD, Lazaridis KN (2016) Duration of inflammatory bowel disease is associated with increased risk of cholangiocarcinoma in patients with primary sclerosing cholangitis and IBD. Am J Gastroenterol 111:705 PubMed DOI PMC

Bajer L, Kverka M, Kostovcik M, Macinga P, Dvorak J, Stehlikova Z, Brezina J, Wohl P, Spicak J, Drastich P (2017) Distinct gut microbiota profiles in patients with primary sclerosing cholangitis and ulcerative colitis. World J Gastroenterol 23:4548–4558 PubMed DOI PMC

Rühlemann MC, Solovjeva MEL, Zenouzi R, Liwinski T, Kummen M, Lieb W, Hov JR, Schramm C, Franke A, Bang C (2020) Gut mycobiome of primary sclerosing cholangitis patients is characterised by an increase of Trichocladium griseum and Candida species. Gut 69:1890–1892 PubMed DOI PMC

Rawla P, Samant H (2023) Primary sclerosing cholangitis. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL). Available from: https://www.ncbi.nlm.nih.gov/books/NBK537181/ PubMed

Trilianos P, Agnihotri A, Ucbilek E, Gurakar A (2016) Greater biosynthetic liver dysfunction in primary sclerosing cholangitis suggests co-existent or impending cholangiocarcinoma. http://www.xiahepublishing.com/ 4:1–4 PubMed PMC

Björnsson E, Lindqvist-Ottosson J, Asztely M, Olsson R (2004) Dominant strictures in patients with primary sclerosing cholangitis. Am J Gastroenterol 99:502–508 PubMed DOI

Gochanour E, Jayasekera C, Kowdley K (2020) Primary sclerosing cholangitis: epidemiology, genetics, diagnosis, and current management. Clin Liver Dis (Hoboken) 15:125–128 PubMed DOI PMC

Chahal D, Shamatutu C, Salh B, Davies J (2020) The impact of primary sclerosing cholangitis or inflammatory bowel disease on cholangiocarcinoma phenotype, therapy, and survival. JGH Open 4:1128 PubMed DOI PMC

Fevery J, Verslype C, Lai G, Aerts R, Van Steenbergen W (2007) Incidence, diagnosis, and therapy of cholangiocarcinoma in patients with primary sclerosing cholangitis. Dig Dis Sci 52:3123–3135 PubMed DOI

Nakanuma Y, Kakuda Y (2015) Pathologic classification of cholangiocarcinoma: new concepts. Best Pract Res Clin Gastroenterol 29:277–293 PubMed DOI

Carpino G, Cardinale V, Folseraas T et al (2019) Neoplastic transformation of the peribiliary stem cell niche in cholangiocarcinoma arisen in primary sclerosing cholangitis. Hepatology 69:622–638 PubMed DOI

Goeppert B, Folseraas T, Roessler S et al (2020) genomic characterization of cholangiocarcinoma in primary sclerosing cholangitis reveals therapeutic opportunities. Hepatology 72:1253–1266 PubMed DOI

Nakamura H, Arai Y, Totoki Y et al (2015) Genomic spectra of biliary tract cancer. Nat Genet 47:1003–1010 PubMed DOI

Churi CR, Shroff R, Wang Y et al (2014) Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications. PLoS ONE. 10.1371/JOURNAL.PONE.0115383 PubMed DOI PMC

Shibata T, Arai Y, Totoki Y (2018) Molecular genomic landscapes of hepatobiliary cancer. Cancer Sci 109:1282 PubMed DOI PMC

Jusakul A, Cutcutache I, Yong CH et al (2017) Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma. Cancer Discov 7:1116–1135 PubMed DOI PMC

Grimsrud MM, Forster M, Goeppert B et al (2024) Whole-exome sequencing reveals novel cancer genes and actionable targets in biliary tract cancers in primary sclerosing cholangitis. Hepatol Commun. 10.1097/HC9.0000000000000461 PubMed DOI PMC

Chmiel P, Gęca K, Rawicz-Pruszyński K, Polkowski WP, Skórzewska M (2022) FGFR inhibitors in cholangiocarcinoma—a novel yet primary approach: where do we stand now and where to head next in targeting this axis? Cells 11:3929 PubMed DOI PMC

Sumbly V, Landry I, Rizzo V (2022) Ivosidenib for IDH1 mutant cholangiocarcinoma: a narrative review. Cureus 14 PubMed PMC

Rizzo A, Ricci AD, Brandi G (2021) Detecting and targeting NTRK gene fusions in cholangiocarcinoma: news and perspectives. Expert Rev Precis Med Drug Dev 6:225–227 DOI

Mody K, Starr J, Saul M, Poorman K, Weinberg BA, Salem ME, VanderWalde A, Shields AF (2019) Patterns and genomic correlates of PD-L1 expression in patients with biliary tract cancers. J Gastrointest Oncol 10:1099 PubMed DOI PMC

Javle M, Borad MJ, Azad NS et al (2021) Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol 22:1290–1300 PubMed DOI